Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 0.86.

  • Kymera Therapeutics' Equity Ratio fell 48.99% to 0.86 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.86, marking a year-over-year decrease of 48.99%. This contributed to the annual value of 0.85 for FY2024, which is 2454.59% up from last year.
  • Per Kymera Therapeutics' latest filing, its Equity Ratio stood at 0.86 for Q3 2025, which was down 48.99% from 0.86 recorded in Q2 2025.
  • Kymera Therapeutics' Equity Ratio's 5-year high stood at 0.86 during Q3 2024, with a 5-year trough of 0.59 in Q1 2021.
  • Its 5-year average for Equity Ratio is 0.77, with a median of 0.76 in 2022.
  • Per our database at Business Quant, Kymera Therapeutics' Equity Ratio surged by 3018.15% in 2021 and then tumbled by 1558.72% in 2023.
  • Quarter analysis of 5 years shows Kymera Therapeutics' Equity Ratio stood at 0.76 in 2021, then increased by 7.13% to 0.81 in 2022, then dropped by 15.59% to 0.69 in 2023, then increased by 24.55% to 0.85 in 2024, then rose by 0.5% to 0.86 in 2025.
  • Its last three reported values are 0.86 in Q3 2025, 0.86 for Q2 2025, and 0.86 during Q1 2025.